Edwards Lifesciences Corp(EW)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #455 of 2,879 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
EW Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Edwards Lifesciences Corp (EW), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EW at 67.6/100 on a 32-signal composite quality model, placing it at rank #455 of 2,879 stocks — the top 25% of the AI-ranked universe. EW scores in the top quartile across balance sheet strength (86.4), revenue scale (81.1), profitability (80.1). Areas of concern include institutional flow (4.3) and earnings quality (5.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Edwards Lifesciences Corp reports quarterly revenue of $1.6B, net income of $380.7M, free cash flow of $-21.1M. EW trades on the NYSE exchange and files with the SEC under CIK 1099800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Edwards Lifesciences Corp directly from SEC EDGAR.
Revenue
Q1 2026
$1.6B
Net Income
Q1 2026
$380.7M
Free Cash Flow
Q1 2026
$-21.1M
D/E Ratio
Q1 2026
0.06
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+11.5% YoYNet Income
-74.3% YoYOperating Income
-8.3% YoYEPS (Diluted)
-73.7% YoYTotal Assets
+4.9% YoYTotal Debt
+0.1% YoYOp. Cash Flow
+194.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $6.07B +11.5% | $5.44B +8.6% | $5.01B +12.2% | $4.46B +1.8% | $4.39B +0.9% | $4.35B |
| Net Income | $1.07B -74.3% | $4.17B +197.7% | $1.40B -7.9% | $1.52B | — | — |
| Operating Income | $1.26B -8.3% | $1.38B +5.3% | $1.31B -12.6% | $1.50B +66.9% | $897.6M -21.7% | $1.15B |
| EPS (Diluted) | $1.83 -73.7% | $6.97 +203.0% | $2.30 -5.7% | $2.44 +87.7% | $1.30 +137.8% | $0.55 |
| Total Assets | $13.70B +4.9% | $13.06B +39.4% | $9.36B +12.9% | $8.29B +14.6% | $7.24B +11.5% | $6.49B |
| Total Debt | $598.3M +0.1% | $597.7M +0.1% | $597.0M +0.1% | $596.3M +0.2% | $595.0M +0.1% | $594.4M |
| Operating Cash Flow | $1.60B +194.2% | $542.3M -39.5% | $895.8M -26.5% | $1.22B +15.5% | $1.05B -10.9% | $1.18B |
Get alerted when EW's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Edwards Lifesciences Corp including:
More Healthcare Companies
View all Healthcare →Put EW on your watchlist
Track score changes the day Edwards Lifesciences Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EW a good stock to buy?
13F Pro's AI-powered analysis of Edwards Lifesciences Corp (EW) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EW are available on the EW stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own EW?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EW. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Edwards Lifesciences Corp's investment landscape.